 |
An oral drug designed to treat uncontrollable laughing and/or crying (also called pseudobulbar affect), a troubling symptom experienced by some people with MS and other neurological disorders, has passed another hurdle by showing positive results in a Phase III trial.
To read more, as reported by the US National MS Society, click here.
Source: US National MS Society
|
